InvestSMART

Prescient Therapeutics Limited (ASX:PTX)

ALERT: Price-sensitive ASX Announcement for PTX
Current share price for PTX : $0.068 -0.009 (-12.34%)+
Announcement
Release
21 Aug 2026 9:32AM
Price at Release
$0.077
Full Release
download
Summary
Prescient Therapeutics Limited's 2026 Annual Report and Appendix 4E outline the financial performance and activities of the company for the year ending 30 June 2026. The company reported a net loss of $7,002,637, a slight improvement from the previous year's loss. This loss was attributed to ongoing research and development expenses, including a noted decrease in the Research and Development Tax Incentive rebate. Financial highlights include a stronger net asset position due to successful capital raisings, increasing the net assets to $14,200,812. The report also detailed share-based payment increases and employment-related expenses, with a notable rise in share-based payments. The company did not pay or declare dividends during the year. The financial statements were audited with an unmodified opinion. The report also mentions events after the reporting period, including the expiration of stock options and the appointment of a new Chief Medical Officer.
Key Points
  • Net loss for the year was $7,002,637.
  • Research and Development Tax Incentive rebate decreased.
  • Net assets increased to $14,200,812 due to capital raisings.
  • No dividends were paid or declared during the financial year.
  • Share-based payments and corporate expenses increased.
  • Financial statements were audited with an unmodified opinion.
  • Post-reporting period events included stock option expirations and a new Chief Medical Officer.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.